Firstly, because they recognize peptide fragments presented on the cell surface by MHC molecules, TCRms can be directed to a wider range of possible targets originating from intracellular tumor antigens, enabling interaction with previously “undruggable” targets [30]. The gene discussed is HLA-C; the disease is neoplasm.